rheumatology
Medicines

TDM and dose reductions won’t benefit all patients but worth it for some

Optimising treatment dosing for inflammatory disorders such as RA is as complex as the disorders themselves, new research from Norway has shown. In one RA study trialling a 50% dose reduction of csDMARDs versus standard dosing in RA patients in remission, researchers found a significant increase in flares over 12 months in the half-dose group. ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic